CXCR4 antagonism corrects neutrophil abnormalities and reduces pneumonia severity in a pharmacological mouse model of CXCR2 loss-of-function-mediated neutropenia
Our findings provide evidence that oral administration of a CXCR4 antagonist can effectively correct blood and BM neutrophil abnormalities and reduce infection susceptibility in a CXCR2 LOF mouse model. These findings suggest potential therapeutic benefits of CXCR4 antagonist therapy in addressing peripheral blood neutropenia and other pathogenic phenotypes in patients with CXCR2 LOF variants.
Authors
- Myriam Defontis
- Arthur G. Taveras
- Chi Huu Nguyen (ORCID: https://orcid.org/0000-0003-4125-224X)
- Katarina Zmajkovicova (ORCID: https://orcid.org/0000-0002-1394-7039)
- Robert Johnson (ORCID: https://orcid.org/0000-0002-3041-0030)
- Sarah Taplin
- Jacob R. Bledsoe (ORCID: https://orcid.org/0000-0002-2387-5462)
- Lars Karlsson (ORCID: https://orcid.org/0000-0002-8804-1899)
- Angelina Sekirnik
Institutions
- Boston Children's Hospital (US)
- TiGenix (Spain) (ES)
- Xeris Pharmaceuticals (United States) (US)
- Institute for Sustainable Development (SI)
- Fraunhofer Austria (AT)
- Egis (France) (FR)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-10
- DOI
- https://doi.org/10.3389/fimmu.2025.1658987
- Citations
- 1
- Primary Topic
- Chemokine receptors and signaling
- Type
- article
- Field-Weighted Citation Impact
- 1.05